News Intervacc AB

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 12:00:00 2026-11-12 EST			5-day change	1st Jan Change
0.6970 ^SEK	-11.44%		-15.10%	-24.57%

11-03	Intervacc AB Announces Real-World Data Demonstrating Nearly 100% Protection With Strangvac	CI
08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

All News

Mentions Relevance

d0d9b459bd4679ef.j7tcxRFKup3kUF8t_A2brh4T0ppWHePZTlxB-0Lrh-U.-uwPs0kOj8rcIRZqkVLOmnt_k_AEKLaALG8ityegv6_A4xvyc3KN0r5hOA

11-03	Intervacc AB Announces Real-World Data Demonstrating Nearly 100% Protection With Strangvac	CI
09-15	Intervacc to present at upcoming International Healthcare Conference	AQ
09-01	Intervacc: Highlights from DNB Carnegie’s Micro Cap Day	AQ
08-24	Intervacc (Q2 Review): Key catalysts nearing	AQ
08-21	Intervacc: In the right direction – Q2 review	AQ
08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ
07-30	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
07-30	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
07-29	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
07-29	Intervacc: New Zealand order validates Strangvac’s position	AQ
07-29	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
07-29	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
06-04	Redeye initiates coverage of Intervacc	AQ
05-22	Intervacc: Positive results	AQ
05-22	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials	AQ
05-22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
05-15	Intervacc: US progress, while European sales still soft – Q1 review	AQ
05-15	Sweden's Intervacc Elects New Chair	MT
05-15	Appoints Emil Billbäck as chairman	RE
05-15	Emil Billbäck appointed new Chair of the Board of Intervacc	AQ
05-13	Intervacc elects Emil Billbäck as chairperson of board	RE
05-13	Report from Annual General Meeting in Intervacc	AQ
05-13	Intervacc AB Announces Board Changes	CI